Resource Center

This section contains international research and may reference indications not approved in all regions. Please consult local approved indications before use.

Filter By:

Search
resources-top-bg

Click on the read more below to request the document

OMER, Israel, Feb 2, 2026 /PRNewswire/ — Pulsenmore Ltd. (NASDAQ, TASE: PLSM), a pioneer in home ultrasound technology, today announced a first commercial engagement with a medical center in the

Pulsenmore and Clalit Health Services Launch First At-Home Follicular Monitoring Service for IVF and Fertility Preservation Commercial agreement potentially valued at approximately $4.5 million over five years following 18 month

We’re excited to share a few key updates from Pulsenmore as we continue to expand our impact in maternal-fetal care. FDA authorization, and what it unlocks Receiving FDA De Novo

Pulsenmore introduces a transformative model for prenatal care - extending ultrasound access beyond the clinic and redefining how we reach and monitor expectant mothers.
RAMAT GAN, Israel, Nov. 3, 2025 /PRNewswire/ -- Pulsenmore Ltd. (TASE: PULS), a pioneer in home ultrasound solutions, today announced that the U.S. Food and Drug Administration (FDA) has granted
resources-bottom-bg

the news pulse

We invite you to keep up to date with the latest updates by registering to our quarterly newsletter

news-pulse-doctor
news-pulse-lady1
news-pulse-couple
news-pulse-lady2
about-collaborations-bottom-bg

FAQ

Frequently asked question

The Pulsenmore was designed to follow ALARA (As Low As Reasonably Achievable) principles as follows:

The system supports only low frequency (2-5MHz), the duration of the scan is limited up to 3 minutes in the App guided mode, or at the clinician’s discretion in the clinician guided mode, only clinician can modify the ultrasound parameters (i.e., depth, gain, frequency etc.), each scan is enabled only upon the approval of a medical professional. The system was authorized by FDA through the de novo classification process.